CoChat
Sign Up
Cited by 2Attention Deficit Hyperactivity DisorderPharmaceutical studies and practicesPharmacology and Obesity Treatment

The DOI matches its Crossref record.

Efficacy and safety of SPN-812 (extended-release viloxazine) in children and adolescents with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis

Open access
Tan, Xin, Xu, Yuejuan, Wang, Shixin, Li, Jiaxuan, Hu, Chunxia, Chen, Zhouqing, Cheng, Qingzhang, Wang, Zhong·2023
DOI 10.37766/inplasy2023.9.0059
Open this paper in CoChat — free accountOpen PDF

Abstract

eview question / Objective P:children and adolescents with ADHD; I:SPN-812; C:placebo; O:ADHD-RS-5, Conners 3-PS, WFIRS-P, CGI-I score,AEs and SAEs; S:RCTs.Condition being studied ADHD (attention deficit hyperactivity disorder) is a widespread and debilitating neuropsychiatric condition that affects children and teenagers.METHODS Participant or population Children and adolescents (6-17 years old) who were diagnosed with ADHD.Intervention Different doses of SPN-812 vs. placebo.Comparator ADHD-RS-5, Conners 3-PS, WFIRS-P, CGI-I score,AEs and SAEs.Study designs to be included Randomized controlled trials.Eligibility criteria Inclusion criteria :(1) The type of study must be an RCT; (2) language: English(3) Subjects: diagnosed ADHD patients (6-17 years old); (4) intervention: different doses of SPN-812 and placebo; (5) Indicators: ADHD-RS-5, Conners 3-PS, WFIRS-P, CGI-I score, AEs and SAEs.Case reports, case reviews, retrospective studies, and cohort studies and studies with active controls were excluded.

Overview

Integrity signals

Registry

Crossref · 10.37766/inplasy2023.9.0059

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cited by

Sorted by citations

See all 2

Related

See all

Metadata

Authors
Tan, X., Xu, Y., Wang, S., Li, J., Hu, C., Chen, Z., Cheng, Q., & Wang, Z.
Affiliations
First Affiliated Hospital of Soochow University (CN)
ORCID
Publisher
INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols
Published
2023-09-16
DOI
10.37766/inplasy2023.9.0059
OpenAlex
W4386797299
Cited by
2
References
0
Citations by year
2025: 2
Type
report
Language
en
Open access
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
attention deficit hyperactivity disorder, children and adolescents, stimulant-free treatment, ADHD symptom severity, adverse events, treatment efficacy and safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of SPN-812 (extended-release viloxazine) in children and adolescents with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.37766/inplasy2023.9.0059
The paper
Tan, X., Xu, Y., Wang, S., Li, J., Hu, C., Chen, Z., Cheng, Q., & Wang, Z. (2023). Efficacy and safety of SPN-812 (extended-release viloxazine) in children and adolescents with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. https://doi.org/10.37766/inplasy2023.9.0059